Form 4: Pyxis Oncology Director Acquires Stock Options
SEC Form 4 Filing
Michael A. Metzger, a director of Pyxis Oncology, acquired stock options for 70,683 shares on June 10, 2024.
Summary
- Michael A. Metzger, a director of Pyxis Oncology, filed a Form 4 on June 10, 2024.
- The filing reports the acquisition of stock options for 70,683 shares of Pyxis Oncology common stock.
- The exercise price of the options is $3.97 per share.
- The options vest in three equal annual installments starting on June 10, 2025, and expire on June 10, 2034.
- Metzger directly owns 70,683 derivative securities following the reported transaction.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing related to stock option grants, which is neither particularly positive nor negative.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders, like directors and officers, trade their company's stock. These filings provide transparency into insider activity and can be monitored for signals about a company's prospects.
Stakeholder Impact
- The stock option grant aligns the director's interests with those of shareholders, incentivizing them to increase the company's value.
Key Dates
| Date | Description |
|---|---|
| 06/10/2024 | Date of earliest transaction (grant of stock options) |
| 06/10/2024 | Date of Form 4 filing |
| 06/10/2025 | First vesting date of the stock options |
| 06/10/2034 | Expiration date of the stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.